In these trials, the inability to comprehend trial-related procedures and risks is a barrier to participation.
We expect a 25% drop-out of patients between inclusion and the follow-up meeting 26 weeks later, due to premature termination of the trial participation, inability to cooperate in the trial, or mortality[ 11].
Severe vomiting, defined as = three times in the 24 hours prior to inclusion in the trial or inability to tolerate oral treatment, or severe diarrhoea defined as ≥ three watery stools per day.
There will be certain restrictions on the defense that are not present in civilian trials, an inability to keep hearsay evidence out, in terms of access to classified information.
One limitation of the FAITH trial is the inability to blind patients, surgeons, and outcome adjudicators.
It is therefore impossible to ascertain whether nonsignificant results are a result of negative trials, where the nonsignificant difference between active treatment and placebo is a consequence of the treatment itself, or a failed trial where the inability to show significance is due to flaws in the trial design and/or execution.
However, one major limitation of these trials is the inability to assign the cause of death with certainty to hypoglycaemia.
There are naturally limitations to non randomised controlled trials including the inability to infer that the change in outcome is directly related to the intervention.
Possible reasons for the failure of disease-modifying drug clinical trials include our inability to diagnose AD before substantial neuronal damage has occurred, as well as track disease progression and treatment response [ 2].
Challenges in translating preclinical studies to clinical trials include the inability of animal models to recapitulate the human disease, variations in breeding and colony maintenance, lack of standards in design, conduct and analysis of animal trials, and publication bias due to under-reporting of negative results in the scientific literature.
